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SUMMARY 
Background: Efficacy of infliximab in treating ulcerative proctitis is unknown. 
Aim: To evaluate clinical, biological and endoscopic efficacy of infliximab therapy in 
refractory proctitis. 
Methods: The charts of 420 patients treated with infliximab for ulcerative colitis were 
reviewed. Thirteen patients were treated with infliximab for refractory ulcerative proctitis in 
six referral centers between 2005 and 2009.  
Results:  Following infliximab therapy induction, 9/13 patients (69%) had a complete 
response (defined as absence of diarrhea and blood), 2/13 (15%) had a partial response and 
2/13 (15%) were primary non-responders. The median follow-up was 17 months (range, 3-
48). Among the 11 patients with clinical response after infliximab induction therapy, 9 (82%) 
patients maintained response at last news. Disappearance of rectal disorders was observed in 
all 9 patients who maintained clinical response at last news. Following infliximab induction 
therapy, the mean CRP level fell from 12.8 mg/L to 4.7 mg/L. Endoscopic evaluation was 
performed before and after infliximab in 7 patients, showing an improvement in mucosal 
lesions in 4 patients, persistent mild endoscopic activity in 2 patients, and no improvement in 
one patient. One patient underwent proctocolectomy.  
Conclusion: Infliximab therapy seems to be effective in inducing and maintaining clinical 
response in refractory ulcerative proctitis.  
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INTRODUCTION 
In population-based studies, ulcerative colitis was confined to the rectum at the time of 
diagnosis in 22% to 59% of patients.1-6 The 2-yr, 5-yr and 10-yr cumulative rate of relapse 
after the first diagnosis was respectively of 42%, 57% and 84% for all patients with ulcerative 
proctitis (UP) at diagnosis.7-9 UP may result in distressing symptoms, including stool 
frequency, tenesmus, urgency and bleeding.8, 10 Despite the significant benefits of rectally 
administered aminosalicylates and corticosteroids,10, 11 some patients with UP and good 
observance fail to improve and require additional medical therapy.  
The management of UP refractory to standard medications remains a challenge in clinical 
practice, as few data are evidence-based.10 Several medications have been tested to treat 
refractory UP. In randomized controlled trials, antibiotics,12-15 cyclosporine enemas16 and oral 
methotrexate17 were not significantly effective to induce and maintain long-term clinical 
response and remission. Azathioprine18, 19 and tacrolimus20  were more effective than 5-
aminosalicylate/mycophenolate mofetil and placebo, respectively, to induce short-term 
clinical response in refractory ulcerative colitis, but were associated with a higher incidence 
of adverse events. Intramuscular methotrexate21 and rectal tacrolimus ointment22,23 have been 
assessed in small open labeled studies, with encouraging results that need to be confirmed in 
large prospective studies. There is a lack of sufficient data or fair results for alternative and 
miscellaneous treatment including nicotine, heparin, short-chain fatty acid or probiotics.24-27 
Although an invasive procedure, appendicectomy has recently shown promising results.28 
Overall, these results remain difficult to interpret due to small sample size and the lack of 
well-designed published studies supporting their efficacy for refractory UP. 
Infliximab (Remicade; Centocor, Malvern, PA), a tumor necrosis factor antagonist, has 
changed the way of treating inflammatory bowel diseases refractory to standard medications. 
Two large placebo-controlled, randomized trials, namely ACT 1 and ACT 2, demonstrated 
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that infliximab is effective to induce and maintain clinical response in ulcerative colitis.29 
However, patients with UP were excluded from both studies. In a retrospective study of 121 
patients treated for ulcerative colitis with infliximab, only 3 patients had UP but were not 
specifically studied.30 In a prospective pilot study evaluating the efficacy of local tacrolimus 
for UP, tacrolimus was prescribed for infliximab failure in 4 out of 8 patients.23 Recently, 
topical administration of infliximab was found to be effective in one patient with chronic 
refractory proctitis.31 
Importantly, patients with UP showing an aggressive disease course, with frequently relapsing 
proctitis and refractory disease to conventional treatment, are more prone to show proximal 
extension at a later date,7-9 and are colectomized to a higher extent.2, 8 Because some data 
suggest that early aggressive treatment of UP may prevent or delay proximal extension, there 
is an urgent need to better evaluate the efficacy of potent therapies such as infliximab in 
treating these patients.32  
The aim of this study was therefore to evaluate the long-term outcome of refractory UP 
treated with infliximab therapy in a retrospective multicenter study.  
 
METHODS 
Study population 
All hospital records of adult (age > 18 yr) patients treated with infliximab for ulcerative colitis 
at 6 tertiary referral centers in France (University Hospitals of Rennes, Nancy, Saint-Etienne, 
Nantes, Lyon, and Nice) between January 2005 and September 2009 were reviewed. A 
centralized diagnostic index was first used to identify all patients with diagnosis of ulcerative 
colitis. The database of these patients with ulcerative colitis was then compared to the 
pharmacy records of all patients treated with infliximab at these six hospitals. All adult 
patients with documented proctitis refractory to standard medication at first infliximab 
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infusion and an established diagnosis of ulcerative colitis based on clinical, radiological, 
endoscopic and/or histological evidence were included. Proctitis was defined according to the 
Montreal classifcation.33 
Infliximab was administered initially at a dose of 5 mg/kg as a 2-h i.v. infusion. Following 
infliximab induction therapy, which consisted of 3 infusions at weeks 0, 2, and 6, the patients 
received various infliximab regimens, depending on the preferences of each treating 
physician. Maintenance treatment was individually tailored by treating physicians. Scheduled 
maintenance treatment was defined as if infliximab was intentionally planned every 8 
weeks.30, 34, 35 All concomitant medications were recorded, and medication was included in the 
analysis only if total drug exposure was superior to 3 months after first infliximab infusion. 
All adverse events occurring during or after the first infliximab infusion and until last news 
were collected. Acute infusion reactions were defined as any adverse event that occurred 
during or within one hour after the infusion of infliximab.30, 34, 35  
All endoscopic and clinical reports mentioning the evolution of UP after first infliximab 
infusion were reviewed.  
Short-term and long-term clinical responses were evaluated as previously described.30, 34, 35 
The “short-term response” was defined as the result of induction therapy with infliximab and 
“long-term response” was defined as clinical efficacy at the maximal follow-up. Both short- 
and long-term clinical responses were defined as complete in the absence of diarrhea and 
blood and if a steroid-sparing effect was noted, and partial if there was marked clinical 
improvement but still persistent rectal blood loss.30, 36 To assess rectal disorders, we also 
recorded the presence of stool urgency, incontinence, tenesmus and rectal pain at first 
infliximab infusion and during the follow-up. Rectal disorders were considered as “present” if 
one of these items was reported, while rectal disorders were defined as “absent” if none was 
recorded. 
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To assess endoscopic activity of proctitis, three levels of activity were defined: (1) normal, (2) 
mild with erythema, friability erosion and lack of spontaneous bleeding, and (3) severe with 
ulceration and spontaneous bleeding. 29 
 
Statistical analysis 
Owing to small sample size, statistical analysis was limited to descriptive statistics. 
Quantitative variables were described as mean ± standard deviation (SD) and categorical 
variables were presented as counts and percent of the cohort.  
 
RESULTS 
Baseline characteristics of the patients 
A total of 420 patients were treated with infliximab for ulcerative colitis at the six referral 
centers between January 2005 and September 2009. A total of 13 patients were treated with 
infliximab for refractory UP. The baseline characteristics at first infliximab infusion are 
indicated in Table 1. The mean age of our population was 47 years (SD=12.7; range, 27-66) 
and the mean duration of UP was 5.4 years (SD=6.9; range 0.2-22.2). Except for patient 2 
who had a corticodependent disease, all patients had activ  UP with diarrhea and/or bloody 
stools. All patients also had rectal disorders at time of first infliximab infusion. 
Only one patient was an active smoker at baseline. One patient had extra-intestinal 
rheumatologic disease. One patient had prior intestinal surgery that was not related to 
ulcerative colitis and consistied in a sigmoidectomy for diverticular disease performed 10 
years before the diagnosis of ulcerative colitis. 
Of the 13 patients, 11 (85 %) had been treated with immunosuppressants (thiopurine, 
methotrexate) before starting infliximab. Two patients had prior exposure to intravenous 
corticosteroid therapy, and two patients had received cyclosporine before infliximab 
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initiation. All patients had received prior rectal 5-amisalicylate and prior oral corticosteroid 
therapy. 
 
Infliximab therapy and concomitant medications 
Infliximab was prescribed for UP refractory to both rectal 5-aminosalicylate and oral 
corticosteroid therapy in all 13 patients, and UP was also refractory to immunosuppressants in 
11 patients.  
All patients received induction therapy with 3 infliximab infusions at weeks 0, 2 and 6. Four 
out of 13 patients (15%) received only infliximab induction therapy, while the 9 remaining 
patients (85%) had scheduled infliximab treatment. In these patients, the mean number of 
infliximab infusions after induction therapy was 7 (S.D. =8.6; range, 1-25).  
Concomitant medications at infliximab therapy initiation are summarized in Table 2. A total 
of 8 patients were treated with concomitant immunosuppressants and 6 patients had 
concomitant corticosteroid therapy. 
 
Short-term clinical and biological efficacy (Table 2) 
Short-term efficacy could be assessed for all 13 patients. Two out of 13 patients (15%) were 
judged as primary non-responders. One primary non-responder had no concomitant treatment, 
while the other one was receiving concomitant oral corticosteroid at the time of infliximab 
initiation. A total of 11 out of 13 (85%) patients experienced clinical improvement after 
treatment with infliximab: complete clinical response was observed for 9 out of the 11 
patients (82%) and a partial response for two subjects (18%). All subjects (n=8) with 
concomitant immunosuppressant had a clinical response, which was judged as complete in 6 
out of the 8 patients. Rectal disorders were improved in 9 out of the 11 primary responders 
(82%).  
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Following infliximab induction therapy, the mean C-reactive protein (CRP) level fell from 
12.8 mg (S.D. =15.1; range, 1-55) to 4.7 mg (S.D. =4.1; range 0.6-12; data available at 
baseline and after induction therapy in 10 of 13 patients). 
 
Long-term outcome: clinical, biological and endoscopic responses 
Information regarding long-term follow-up was available for all patients (n=13). After a 
median follow-up of 17 months (SD 13 months; range 3-48), the evaluation of clinical activity 
at last news revealed a partial (n=2) or complete (n=7) clinical response in 9 of the 11 primary 
responders (82%). Of note, rectal disorders disappeared in all 9 patients.  
The 4 remaining patients had symptomatic disease at last news, including the 2 patients who 
were considered as primary non-responders. Both of these patients  (Patients 5 and 10) were 
being treated with oral corticosteroid at last news. Two patients (Patients 2 and 8) who were 
considered as primary responders lost response to infliximab over time and were secondary 
non-responders: one patient treated with scheduled infliximab therapy without concomitant 
immunosuppressant had a disease extension to left-sided colitis after discontinuation of 
corticosteroid therapy and finally underwent proctocolectomy (Patient 2). The other one 
(Patient 8) had complete short-term clinical response with disappearance of diarrhea and 
blood in stools, but as patient 2 had a persistent rectal disorder after infliximab induction 
therapy. This patient had an early relapse after infliximab induction therapy and did not 
experience any clinical improvement despite infliximab optimization by dose escalation at the 
fourth infusion. Treatment was changed to oral tacrolimus and methotrexate without any 
response on clinical disease activity or rectal disorder.  
Among the 8 patients who were primary responders and had concomitant immunosuppressant 
at baseline, 7 patients had maintained their clinical response without any rectal disorder at last 
news. 
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During follow-up, infliximab optimization was necessary in 3 patients. Two patients (patients 
1 and 9) had a complete clinical response at last news, whereas the third one (Patient 8) had 
not experienced any improvement in clinical symptoms despite dose escalation and was 
considered a secondary non-responder. 
At last news, the CRP level was available for 7 patients. When including all 7 subjects in the 
analysis, the mean CRP level was 14.4 mg/L (S.D. = 22.2; range 0.5-59). Excluding primary 
non-responders did not influence this result, with a mean CRP level of 14.1 mg/L (S.D. =25.2; 
range 0.5-59). When excluding both primary and secondary non-responders, the mean CRP 
level was only 2.9 mg/L (S.D. =2; range 0.5-5). 
All patients had endoscopic evaluation at baseline. During follow-up, 7 patients also had 
endoscopic evaluation of the rectum after infliximab initiation. This showed an improvement 
in mucosal lesions in 4 patients (complete mucosal healing in 2 patients and mild endoscopic 
activity in 2 patients), stable endoscopic lesions with persistent mild endoscopic disease in 
two patients, and persistent severe rectal disease in one patient, as defined above. 
Interestingly, endoscopic response was generally associated with clinical response: the two 
patients with complete mucosal healing at last news who had severe (patient 4) and mild 
(patient 13) lesions at infliximab initiation were in clinical response at last news, whereas 
patient 12 with severe mucosal lesions persisting after infliximab induction therapy was a 
secondary non-responder to infliximab therapy. The 4 remaining patients had mild endoscopic 
activity at last news: patients 1 and 9, who respectively had severe and mild endoscopic 
lesions at time of infliximab initiation, had a complete clinical response at last news. Hence, 
there was a discrepancy between endoscopic and clinical response in only two patients: 
patients 5 and 8, who respectively had severe or mild endoscopic lesions at baseline, were 
primary and secondary non-responders at last news despite mild endoscopic activity after 
infliximab therapy initiation.  
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Adverse events 
Infliximab infusions were generally well tolerated. None of the 13 patients had any acute 
infusion reaction. Only two patients experienced adverse events. One developed psoriasiform 
lesions leading to infliximab discontinuation. The other developed several infections, with 
left-sided diverticulitis and bursitis of the knee. He was treated with concomitant 
immunosuppressant and oral steroid therapy. Both infections had a favorable outcome after 
administration of broad-spectrum antibiotics, so infliximab therapy could be continued. No 
opportunistic, tuberculosis infections, malignancies or lymphoma were observed throughout 
the follow-up period. 
 
DISCUSSION 
This study shows for the first time that infliximab treatment may be effective for both 
induction and maintenance of clinical response in refractory UP.  
Two randomized trials, namely ACT 1 and ACT 2, demonstrated the efficacy of infliximab in 
ulcerative colitis, but UP were excluded from both studies29, whereas the monocenter 
retrospective study from Leuven did not specifically report the outcome of 3 patients with UP 
treated with infliximab.30 
Following infliximab induction therapy, 11 out of 13 (85%) patients experienced clinical 
improvement after treatment with infliximab, with 9 of the 11 (82%) also experiencing 
improvement in rectal disorders. Long-term outcome showed a complete clinical response for 
half of the patients with refractory UP. These results are in line with previous reports showing 
a clinical response in patients with pancolitis or left-sided colitis treated with infliximab at 
short term in about 63-69.4% of patients and at long term in 38.8-43% of patients.29, 30 Of 
note, 9 of the 11 primary responders maintained a complete response at maximal follow-up, 
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as judged by disease activity and the absence of rectal disorders. This finding is also 
consistent with that obtained in a large monocenter retrospective study evaluating infliximab 
in left-sided and pancolitis, and showing that 68% of patients with initial response to 
infliximab had sustained clinical response during follow-up.30 Because infliximab efficacy for 
UP was broadly similar to that reported for left-sided colitis and extensive colitis, our results 
suggest that UP may be included in large international clinical trials evaluating the efficacy of 
anti-TNF agents in ulcerative colitis.  
Interestingly, clinical response was accompanied by a decrease in CRP levels and an 
improvement in endoscopic lesions of the rectum. The drop in CRP levels is a known factor 
associated with clinical response in ulcerative colitis.30 Mucosal lesions were improved in 4 of 
the 7 patients with endoscopic assessment after infliximab initiation, thus confirming the 
efficacy of infliximab therapy in this indication. 
Meucci et al. reported that 14% of patients with UP presented one or more features consistent 
with a refractory disease, indicating that, in some patients with UP, the disease course is not 
as mild as generally assumed.8 This aggressive course was associated with an increased risk 
of proximal disease extension and finally colectomy.2, 8 In our series, only one patient 
relapsed after infliximab induction: he progressed to pancolitis and finally underwent 
proctocolectomy. Of note, the safety profile of infliximab was consistent with previous 
experience with this drug in UC.29, 30, 34 Overall, these results indicate that infliximab may be 
effective in treating refractory UP. 
We were not able to look for predictors of response to infliximab due to small sample size. 
Despite this limitation, patients with concomitant immunosuppressant administration seemed 
to have higher rates of clinical response and a longer duration of response to infliximab. 
Another limitation is the lack of control arm. However, the rates of response to placebo in 
patients with severe and resistant ulcerative colitis in randomized control trials are low, 
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ranging from 10 to 33% at short term and from 6.6 to 14% in the long term.20, 29 In addition, 
only patients who had active disease despite treatment with conventional therapy, including 
local aminosalicylate and corticosteroid therapy, were included in the study.  
Importantly, the median follow-up was 17 months. A long-term follow-up is required to 
assess the sustained efficacy of medical treatment in refractory UP, which is known to relapse 
frequently, and because refractory disease is more prone to having a complicated outcome.8, 9, 
14
 Furthermore, this was a multicenter study. Infliximab therapy is rarely used to treat UP in 
clinical practice. By screening a total of 420 patients treated with anti-TNF therapy for 
ulcerative colitis at 6 referral centers in France, we were able to identify and analyze the 
data of 13 patients. Finally, because of the retrospective study design and the inherent bias in 
interpreting clinical response on medical records, we decided to assess clinical response not 
only by using the judgment of the treating physician but also by recording the presence or not 
of objective Mayo criteria such as diarrhea and blood in the stools.30, 36 In addition, the 
absence of rectal disorders was defined as the absence of all predefined items, namely stool 
urgency, incontinence, tenesmus and rectal pain. 
Collectively, our findings indicate that infliximab may be effective and safe in inducing and 
maintaining a clinical response in patients with refractory UP. It is unlikely that a randomized 
controlled trial will ever be carried out to evaluate the efficacy of infliximab in refractory UP. 
However, because of the retrospective study design of our study and small sample size, 
infliximab efficacy in treating ulcerative proctitis needs to be confirmed in larger prospective 
studies. Pending these results, infliximab should be used only in patients with disease 
refractory to all available medications. The optimal drug regimen as well as the optimal 
duration of treatment remain to be determined. 
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Table 1: Baseline characteristics of 13 patients with refractory ulcerative proctitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Previous treatment 
  Patient 
No. 
Sex Age (yr) 
Disease 
duration 
(months) 
Previous 
surgery Enema, 
ointment, 
suppository 
Systemic 
medications 
Number of 
bowel 
movements/
24 hours 
 
Presence of 
bloody stools* 
 
Rectal 
disorders 
Endoscopic 
activity 
1 M 61 267 NO ASA ASA,CS, IS, Cyclo 6 Severe Present Severe 
2 M 46 131 NO ASA ASA,CS, IS 4 None Present Normal 
3 M 65 45 NO ASA, CS ASA,CS, IS 6 Mild Present Mild 
4 M 31 24 NO ASA ASA,CS, IS 10 Severe Present Severe 
5 M 55 195 NO ASA, CS ASA,CS, IS 15 Severe Present Severe 
6 M 54 75 NO ASA ASA,CS, IS 15 Severe Present Severe 
7 M 42 12 NO ASA ASA,CS 10 Mild Present Mild 
8 M 28 12 NO ASA, CS ASA,CS, IS, Cyclo 3 Mild Present Mild 
9 M 37 3 NO ASA, CS CS, IS 2 None Present Mild 
10 M 26 44 NO ASA, CS ASA,CS 20 Mild Present Mild 
11 M 54 7 Sigmoidectomy ASA, CS ASA, CS, IS 8 Severe Present Severe 
12 F 55 4 NO ASA, CS ASA,CS, IS 8 Severe Present Severe 
13 M 42 29 NO ASA, CS ASA,CS, IS 6 Severe Present Mild 
M, Male; F, female; yr, years ; IFX, infliximab; ASA, aminosalicylate; IS, immunosuppressant (azathioprine, 6 mercaptopurine, methotrexate); CS, 
corticosteroid; Cyclo, cyclosporine 
*As judged by their physician. 
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Table 2: Short-term and long-term responses to infliximab in the 13 patients with refractory 
ulcerative proctitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Short-term response Long-term response Patient 
No. 
Number 
of  IFX 
infusions 
Concomitant 
medications 
Clinical 
response 
Rectal 
disorders 
Follow-
up 
(months) 
Maintenance 
treatment 
(IFX) 
Clinical 
response 
Rectal 
disorders 
Endoscopy 
at last 
news 
Treatment 
at last 
news 
1 17 ASA, IS Complete Absent 28 YES Complete Absent Mild IFX 
2 4 ASA, CS Complete Present 21 YES Absent - - Procto-
colectomy 
3 4 None Complete Absent 5 YES Complete Absent - IFX 
4 18 CS, IS Complete Absent 28 YES Complete Absent 
Complete 
mucosal 
healing 
IFX 
5 3 CS Absent Present 29 Primary non 
responder Absent Present Mild 
CS 
6 6 CS, IS Partial Absent 12 YES Complete Absent - IFX 
7 4 ASA Complete Absent 3 YES Complete Absent - IFX 
8 4 IS Complete Present 9 YES Absent Present Mild Tacrolimus IS 
9 28 CS, IS Complete Absent 48 YES Complete Absent Mild IFX, IS 
10 3 None Absent Present 6 Primary non 
responder Absent Present - 
CS 
11 3 ASA, IS Partial Absent 6 NO Partial Absent - IFX 
12 3 CS, IS Complete Absent 18 NO Partial Absent Severe ADA*, CS, IS 
13 9 ASA, IS Complete Absent 12 YES Complete Absent 
Complete 
mucosal 
healing 
IFX 
 IFX, infliximab; ASA, aminosalicylate; IS, immunosuppressant (azathioprine, 6 mercaptopurine, methotrexate); ADA, adalimumab 
*Switch from infliximab to adalimumab due to patient preference. 
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